Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05572658 · ClinicalTrials.gov registry record
Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study
A clinical trial, sponsored by ModernaTX.
- Completed
- Registry status
- 10,994
- Enrollment target
NCT05572658: Completed study, sponsored by ModernaTX.
NCT05572658 is a clinical trial that has completed, run by ModernaTX. The registered enrollment target is 10,994 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05572658 has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- 10,994 participants
- Enrollment target
Study Summary
The main goal of this observational study is to describe the health and economic outcomes associated with use of the Moderna mRNA-1345 vaccine.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL mRNA-1345
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,994 participants |
| Start Date | 2022-09-15 |
| Est. Completion | 2023-09-30 |
What the finished NCT05572658 record still lists
NCT05572658 is an observational study that tracks outcomes without assigning an intervention. Its 10,994 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05572658 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05572658 about?
NCT05572658 is a clinical study titled "Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study". The main goal of this observational study is to describe the health and economic outcomes associated with use of the Moderna mRNA-1345 vaccine.
What is the current status of trial NCT05572658?
This trial is currently completed. The enrollment target is 10,994 participants. The study started on 2022-09-15. Estimated completion is 2023-09-30.
What interventions are being tested in trial NCT05572658?
The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1345 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05572658?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06531824 · 11,000 participants · Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
- NCT07136012 · 11,000 participants · Phase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- NCT07181109 · 11,000 participants · Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
- NCT06736951 · 10,890 participants · NA
Modifying the Inpatient Environment to Reduce Delirium in Older Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI